Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated Treatment for Cocaine and Mood Disorders
NCT00227812Phase 2Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Apr 2001
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupropion in cocaine dependence, major depressive disorder (MDD) and Substance-induced depressive disorder (SMIDD) (4 arms), sponsored by National Institute on Drug Abuse. Primary endpoint: Urine toxicology for cocaine at 12 weeks. Started Apr 2001; status: completed.
02
Drugs
bupropion
03
Conditions
cocaine dependencemajor depressive disorder (MDD)Substance-induced depressive disorder (SMIDD)
Beyond the preview
Go deeper on NCT00227812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227812.